Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity
Phillip C.C. Liu(Incyte (United States)), Jordan S. Fridman(Incyte (United States))
Cited by 19